John E. Bailey - Jan 3, 2023 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role: President and CEO, Director
Signature: /s/ James Stillman Hanson, attorney-in-fact
Stock symbol: GTHX
Transactions as of: Jan 3, 2023
Transactions value $: -$218,714
Form type: 4
Date filed: 1/5/2023, 07:23 PM
Previous filing: Jan 5, 2022
Next filing: May 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTHX	Common Stock	Award	$0	+80.7K	+34.6%	$0.00	314K	Jan 3, 2023	Direct	F1, F2, F3
transaction	GTHX	Common Stock	Sale	-$187K	-32K	-10.2%	$5.85	282K	Jan 3, 2023	Direct	F4, F5, F6
transaction	GTHX	Common Stock	Sale	-$31.3K	-5.61K	-1.99%	$5.58	276K	Jan 4, 2023	Direct	F4, F7, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTHX	Stock Options (Right to buy)	Award	$0	+161K		$0.00	161K	Jan 3, 2023	Common Stock	161K	$5.73	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2	Each RSU represents a contingent right to receive one share of Issuer common stock.
F3	Represents (i) 44,986 shares of common stock; (ii) 142,222 RSUs from award granted on January 1, 2021; (iii) 46,000 RSUs from award granted on January 3, 2022; and (iv) 80,700 RSUs from award granted on January 3, 2023.
F4	The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5	The price represents the weighted average price with a low of $5.77 and a high of $5.94. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	Represents (i) 84,078 shares of common stock; (ii) 71,111 RSUs from award granted on January 1, 2021; (iii) 46,000 RSUs from award granted on January 3, 2022; and (iv) 80,700 RSUs from award granted on January 3, 2023.
F7	The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8	Represents (i) 89,971 shares of common stock; (ii) 71,111 RSUs from award granted on January 4, 2021; (iii) 34,500 RSUs from award granted on January 3, 2022; and (iv) 80,700 RSUs from award granted on January 3, 2023.
F9	The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:

Note: On January 3, 2023, the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report.